TABLE 1.
Baseline characteristics of included studies (n = 6).
| Register id | Biosimilar | Participants number | Age | Female | BMI | Disease duration | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | C | I | C | I | C | I | C | I | C | ||
| NCT01270997 | HD203 | 147 | 146 | 51.0 ± 12.0 | 51.3 ± 12.4 | 101 (87.8%) | 101 (85.6%) | 22.5 ± 3.4 | 22.8 ± 3.5 | 7.19 ± 7.39 | 8.05 ± 7.43 |
| NCT01895309 | SB4(Benepali) | 299 | 297 | 52.1 ± 11.72 | 51.6 ± 11.63 | 249 (83.3%) | 253 (85.2%) | 26.8 ± 5.51 | 26.3 ± 5.3 | 6.0 ± 4.2 | 6.2 ± 4.41 |
| NCT02638259 | GP2015(Erelzi) | 186 | 190 | 55.2 ± 11.22 | 53.1 ± 12.7 | 158 (84.9%) | 150 (78.9%) | \ | 8.79 ± 8.25 | 8.18 ± 6.92 | |
| NCT03332719 | EtaBS(Enerceptan) | 99 | 50 | 50.2 ± 10.8 | 46.3 ± 11.6 | 85 (85.9%) | 42 (84%) | 28.4 ± 5.1 | 27.9 ± 4.9 | 10.6 ± 8.8 | 10.5 ± 7 |
| NCT02357069 | LBEC0101 | 187 | 187 | 52.8 ± 11.6 | 55.5 ± 10.9 | 150 (81.1%) | 166 (88.8%) | — | 7.6 ± 7.6 | 7.8 ± 7.6 | |
| NCT02115750 | CHS-0214 | 324 | 320 | — | 260 (80.2%) | 254 (79.4%) | — | — | |||
I, interventions, etanercept biosimilars; C, comparisons, etanercept originators (Enbrel®); BMI, body mass index.